دورية أكاديمية
أعرض في EDS

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.

التفاصيل البيبلوغرافية
العنوان: Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
المؤلفون: Porta FM; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy., Sajjadi E; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Venetis K; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy., Frascarelli C; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Cursano G; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy., Guerini-Rocco E; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Fusco N; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy., Ivanova M; Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, 20122 Milan, Italy.
المصدر: Journal of personalized medicine [J Pers Med] 2023 Jul 23; Vol. 13 (7). Date of Electronic Publication: 2023 Jul 23.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101602269 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4426 (Print) Linking ISSN: 20754426 NLM ISO Abbreviation: J Pers Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2011-
مستخلص: Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis and disease recurrence. The limited treatment options and the development of resistance to chemotherapy make it particularly difficult to manage these patients. However, recent research has been shifting its focus towards biomarker-based approaches for TNBC, with a particular emphasis on the tumor immune landscape. Immune biomarkers in TNBC are now a subject of great interest due to the presence of tumor-infiltrating lymphocytes (TILs) in these tumors. This characteristic often coincides with the presence of PD-L1 expression on both neoplastic cells and immune cells within the tumor microenvironment. Furthermore, a subset of TNBC harbor mismatch repair deficient (dMMR) TNBC, which is frequently accompanied by microsatellite instability (MSI). All of these immune biomarkers hold actionable potential for guiding patient selection in immunotherapy. To fully capitalize on these opportunities, the identification of additional or complementary biomarkers and the implementation of highly customized testing strategies are of paramount importance in TNBC. In this regard, this article aims to provide an overview of the current state of the art in immune-related biomarkers for TNBC. Specifically, it focuses on the various testing methodologies available and sheds light on the immediate future perspectives for patient selection. By delving into the advancements made in understanding the immune landscape of TNBC, this study aims to contribute to the growing body of knowledge in the field. The ultimate goal is to pave the way for the development of more personalized testing strategies, ultimately improving outcomes for TNBC patients.
References: Mod Pathol. 2020 Sep;33(9):1746-1752. (PMID: 32300181)
Anticancer Agents Med Chem. 2022;22(4):787-800. (PMID: 34229592)
Cancer Sci. 2020 Jul;111(7):2647-2654. (PMID: 32449246)
Onco Targets Ther. 2019 Dec 30;12:11541-11547. (PMID: 31920342)
Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542)
Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411)
JCO Oncol Pract. 2023 Apr;19(4):167-179. (PMID: 36608303)
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016. (PMID: 33523233)
J Oncol Pharm Pract. 2022 Aug 15;:10781552221119797. (PMID: 35971313)
Diagn Pathol. 2021 Oct 25;16(1):94. (PMID: 34689789)
N Engl J Med. 2018 Nov 29;379(22):2108-2121. (PMID: 30345906)
Future Oncol. 2021 Apr;17(10):1209-1218. (PMID: 33289433)
J Pathol. 2020 Apr;250(5):667-684. (PMID: 32129476)
Oncotarget. 2015 Mar 10;6(7):5449-64. (PMID: 25669979)
J Clin Oncol. 2014 Sep 20;32(27):2959-66. (PMID: 25071121)
Breast Cancer. 2018 Jan;25(1):34-42. (PMID: 28488168)
Br J Cancer. 2023 Jun;128(11):2044-2053. (PMID: 36966236)
Breast. 2021 Dec;60:238-244. (PMID: 34768219)
Hum Pathol. 2019 Apr;86:108-114. (PMID: 30633926)
J Thorac Oncol. 2017 Feb;12(2):208-222. (PMID: 27913228)
Cancers (Basel). 2022 Apr 23;14(9):. (PMID: 35565233)
NPJ Breast Cancer. 2021 Dec 1;7(1):150. (PMID: 34853355)
J Pers Med. 2022 Dec 07;12(12):. (PMID: 36556243)
Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935)
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. (PMID: 34754128)
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. (PMID: 33580222)
Front Immunol. 2023 May 04;14:1149747. (PMID: 37215143)
Cancers (Basel). 2022 Feb 28;14(5):. (PMID: 35267561)
Adv Anat Pathol. 2019 Jul;26(4):270-279. (PMID: 30932972)
J Natl Cancer Inst. 2022 May 9;114(5):664-675. (PMID: 34286340)
Nat Med. 2019 Jun;25(6):920-928. (PMID: 31086347)
NPJ Breast Cancer. 2021 May 26;7(1):61. (PMID: 34039982)
J Clin Oncol. 2010 Jan 1;28(1):105-13. (PMID: 19917869)
Pathology. 2021 Feb;53(2):141-156. (PMID: 33388161)
Expert Opin Biol Ther. 2022 Mar;22(3):345-348. (PMID: 34930070)
Cancer Res. 2017 Sep 15;77(18):4755-4762. (PMID: 28904067)
J Immunother Cancer. 2018 Jan 23;6(1):8. (PMID: 29357948)
Front Oncol. 2022 Jul 18;12:910976. (PMID: 35924147)
ESMO Open. 2017 May 2;2(2):e000150. (PMID: 28761741)
Immunol Rev. 2008 Aug;224:166-82. (PMID: 18759926)
Cancers (Basel). 2023 Jan 03;15(1):. (PMID: 36612317)
Int J Cancer. 2021 Aug 1;149(3):728-740. (PMID: 33851412)
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. (PMID: 29346180)
Ecancermedicalscience. 2017 Aug 15;11:759. (PMID: 28900472)
NPJ Breast Cancer. 2022 Apr 21;8(1):52. (PMID: 35449176)
Cancers (Basel). 2022 May 20;14(10):. (PMID: 35626126)
Sci Rep. 2018 Nov 26;8(1):17343. (PMID: 30478349)
NPJ Breast Cancer. 2020 May 12;6:17. (PMID: 32411819)
Anticancer Res. 2021 Apr;41(4):2133-2140. (PMID: 33813424)
JNCI Cancer Spectr. 2018 Dec 13;2(4):pky056. (PMID: 31360876)
J Thorac Oncol. 2019 Jan;14(1):45-53. (PMID: 30296485)
Front Immunol. 2022 Oct 28;13:1018962. (PMID: 36389779)
J Pathol. 2019 Nov;249(3):286-294. (PMID: 31355445)
Biomedicines. 2022 Oct 08;10(10):. (PMID: 36289773)
Ther Adv Med Oncol. 2023 Jan 19;15:17588359221146129. (PMID: 36743524)
Nat Rev Clin Oncol. 2019 Nov;16(11):703-715. (PMID: 31399699)
Transl Cancer Res. 2020 Jul;9(7):4060-4064. (PMID: 35117775)
Int J Mol Sci. 2023 Mar 10;24(6):. (PMID: 36982402)
J Pathol Transl Med. 2020 Jan;54(1):34-44. (PMID: 31693827)
Mol Cancer Ther. 2015 Apr;14(4):847-56. (PMID: 25695955)
Curr Treat Options Oncol. 2023 Jun;24(6):628-643. (PMID: 37079257)
Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. (PMID: 28420726)
Biosci Rep. 2020 Jul 31;40(7):. (PMID: 32602545)
NPJ Breast Cancer. 2022 Dec 30;8(1):134. (PMID: 36585404)
Crit Rev Oncol Hematol. 2022 Apr;172:103643. (PMID: 35217131)
Histopathology. 2016 Jul;69(1):25-34. (PMID: 26588661)
Front Oncol. 2021 Mar 04;11:570623. (PMID: 33747906)
Appl Immunohistochem Mol Morphol. 2022 Sep 1;30(8):549-556. (PMID: 36036647)
Breast Cancer Res. 2022 Oct 10;24(1):67. (PMID: 36217150)
Am J Pathol. 2020 Jul;190(7):1491-1504. (PMID: 32277893)
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. (PMID: 30787022)
J Thorac Oncol. 2018 Sep;13(9):1302-1311. (PMID: 29800747)
Histopathology. 2023 Jan;82(1):17-35. (PMID: 36468263)
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. (PMID: 30640753)
Virchows Arch. 2019 Nov;475(5):599-608. (PMID: 31267201)
Mod Pathol. 2020 Jan;33(1):4-17. (PMID: 31383961)
Cancers (Basel). 2023 May 24;15(11):. (PMID: 37296857)
Genes Chromosomes Cancer. 2022 Jun;61(6):314-321. (PMID: 34837268)
J Breast Cancer. 2020 Jun 01;23(3):303-313. (PMID: 32595992)
Clin Lung Cancer. 2015 Sep;16(5):385-90. (PMID: 25937270)
Ann Oncol. 2019 Aug 1;30(8):1279-1288. (PMID: 31095287)
J Clin Oncol. 2015 Mar 20;33(9):983-91. (PMID: 25534375)
Pathol Res Pract. 2021 Oct;226:153606. (PMID: 34530255)
Front Med. 2021 Feb;15(1):1-10. (PMID: 32789731)
Int J Mol Sci. 2021 Nov 12;22(22):. (PMID: 34830134)
Curr Breast Cancer Rep. 2019 Dec;11(4):303-310. (PMID: 33312344)
Cancer Med. 2023 May;12(9):10725-10737. (PMID: 36916425)
J Pathol Inform. 2019 Mar 08;10:9. (PMID: 30984469)
Int J Mol Sci. 2022 Feb 23;23(5):. (PMID: 35269607)
Histopathology. 2021 Mar;78(4):567-577. (PMID: 32936950)
Breast Care (Basel). 2020 Oct;15(5):481-490. (PMID: 33223991)
EBioMedicine. 2021 Aug;70:103492. (PMID: 34280779)
Cancers (Basel). 2019 Jul 22;11(7):. (PMID: 31336685)
Histopathology. 2022 Jan;80(2):397-406. (PMID: 34496080)
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41. (PMID: 26667975)
Ann Oncol. 2019 Mar 1;30(3):405-411. (PMID: 30475947)
Histopathology. 2018 Sep;73(3):397-406. (PMID: 29660160)
NPJ Precis Oncol. 2023 Jan 27;7(1):14. (PMID: 36707660)
Arch Pathol Lab Med. 2019 Mar;143(3):330-337. (PMID: 30028179)
Crit Rev Oncol Hematol. 2022 Oct;178:103776. (PMID: 35934262)
J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743. (PMID: 34097070)
Mol Diagn Ther. 2018 Feb;22(1):1-10. (PMID: 29119407)
Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. (PMID: 35240902)
NPJ Breast Cancer. 2022 Feb 28;8(1):26. (PMID: 35228530)
J Clin Med. 2023 Jan 26;12(3):. (PMID: 36769602)
فهرسة مساهمة: Keywords: PD-L1; TNBC; artificial intelligence; biomarkers; breast cancer; immune landscape; microsatellite instability; mismatch repair; tumor-infiltrating lymphocytes
تواريخ الأحداث: Date Created: 20230729 Latest Revision: 20230801
رمز التحديث: 20230801
مُعرف محوري في PubMed: PMC10381494
DOI: 10.3390/jpm13071176
PMID: 37511789
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-4426
DOI:10.3390/jpm13071176